Literature DB >> 9177233

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.

K Shiraki1, N Tsuji, T Shioda, K J Isselbacher, H Takahashi.   

Abstract

Fas ligand (FasL) plays a pivotal role in lymphocyte cytotoxicity and the maintenance of immunological homeostasis. Since FasL has been implicated in the existence of immunologically privileged body sites by inducing apoptosis of activated T lymphocytes, we investigated the expression of FasL in human colon cancers. We found that two out of seven primary tumors and all four hepatic metastatic tumors of surgically obtained colonic adenocarcinoma expressed FasL mRNA and protein, detected by reverse transcription-coupled PCR and by immunohistochemical staining, respectively. Expression of FasL was not detected in normal colonic epithelial cells. FasL mRNA was also expressed in some human colonic adenocarcinoma cell lines including SW480, SW1116, and LS180 cells. Cell-surface-associated FasL was detected in these human colon cancer cells by fluorescence immunocytochemical staining. In addition, the expressed FasL was demonstrated to be functional, since coculture experiments using FasL-expressing SW480 cells resulted in apoptosis of Jurkat T leukemia cells that are sensitive to Fas-mediated apoptosis, and this process was specifically inhibited by the neutralizing anti-human FasL antibody. Thus, our findings and other data suggest an alternative mechanism that enables tumors to evade immune destruction by inducing apoptosis in activated T lymphocytes. Furthermore, constitutive expression of FasL in hepatic metastatic tumors suggests that FasL may also be important in their colonization in the liver through induction of apoptosis in the surrounding Fas-expressing hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177233      PMCID: PMC21065          DOI: 10.1073/pnas.94.12.6420

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

Authors:  T Brunner; R J Mogil; D LaFace; N J Yoo; A Mahboubi; F Echeverri; S J Martin; W R Force; D H Lynch; C F Ware
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

2.  Fas-mediated apoptosis in primary cultured mouse hepatocytes.

Authors:  R Ni; Y Tomita; K Matsuda; A Ichihara; K Ishimura; J Ogasawara; S Nagata
Journal:  Exp Cell Res       Date:  1994-12       Impact factor: 3.905

Review 3.  Current concepts in metastasis.

Authors:  A K Nigam; M Pignatelli; P B Boulos
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

4.  Local immunity and metastasis of colorectal carcinoma.

Authors:  Y Kubota; K Sunouchi; M Ono; T Sawada; T Muto
Journal:  Dis Colon Rectum       Date:  1992-07       Impact factor: 4.585

5.  Human Fas ligand: gene structure, chromosomal location and species specificity.

Authors:  T Takahashi; M Tanaka; J Inazawa; T Abe; T Suda; S Nagata
Journal:  Int Immunol       Date:  1994-10       Impact factor: 4.823

6.  Role of Fas ligand in apoptosis induced by hepatitis C virus infection.

Authors:  E Mita; N Hayashi; S Iio; T Takehara; T Hijioka; A Kasahara; H Fusamoto; T Kamada
Journal:  Biochem Biophys Res Commun       Date:  1994-10-28       Impact factor: 3.575

7.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

Authors:  J Dhein; H Walczak; C Bäumler; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

Review 8.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

Review 9.  Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review.

Authors:  J C Underwood
Journal:  Br J Cancer       Date:  1974-12       Impact factor: 7.640

10.  Fas ligand mediates activation-induced cell death in human T lymphocytes.

Authors:  M R Alderson; T W Tough; T Davis-Smith; S Braddy; B Falk; K A Schooley; R G Goodwin; C A Smith; F Ramsdell; D H Lynch
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

View more
  54 in total

1.  Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization.

Authors:  Hiroshi Okano; Katsuya Shiraki; Yutaka Yamanaka; Hidekazu Inoue; Tomoyuki Kawakita; Yukiko Saitou; Yumi Yamaguchi; Naoyuki Enokimura; Keiichi Ito; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

2.  Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.

Authors:  Wei Zhang; Er-Xun Ding; Qiang Wang; Da-Qiao Zhu; Jin He; Yu-Li Li; Yuan-He Wang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

3.  Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Authors:  D Zagury; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B.

Authors:  Yukiko Saitou; Katsuya Shiraki; Takenari Yamanaka; Kazumi Miyashita; Tomoko Inoue; Yutaka Yamanaka; Yumi Yamaguchi; Naoyuki Enokimura; Norihiko Yamamoto; Keiichi Itou; Kazushi Sugimoto; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

6.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 7.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

8.  Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines.

Authors:  Jing-Yuan Fang; Juan Lu; Ying-Xuan Chen; Li Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: its implications on tumor volume, nodal involvement, and survival.

Authors:  Michael Bergqvist; Daniel Brattström; Kristina Lamberg; Patrik Hesselius; Johan Wernlund; Anders Larsson; Gunnar Wagenius
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

10.  Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.

Authors:  Xiao-Zhong Wang; Xiao-Chun Chen; Yun-Xin Chen; Li-Juan Zhang; Dan Li; Feng-Lin Chen; Zhi-Xin Chen; Hong-Ying Chen; Qi-Ming Tao
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.